clinical trial · NCT07479667
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
Shanghai Cell Therapy Group Co.,Ltd·phase1·recruiting·n = 8
Solid CancersAdjuvant TherapyArmored Dendritic Cell Injection
brief summary
This study is a single-arm, open-label, single-administration dose-escalation study.
started
Feb 5, 2026
primary completion
Dec 31, 2028
completion
Jun 30, 2029
last updated
Mar 18, 2026
official title
An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol